FDA Approves Gilead ’s Vemlidy (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy ® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news